Liang Wu

Dr. Liang Wu

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
LWLiang Wu
Liang Wu
KBKarin Boer
Karin Boer
WWWouter W. Woud
Wouter W. Woud
SUSuwasin Udomkarnjananun
Suwasin Udomkarnjananun
DHDennis A. Hesselink
Dennis A. Hesselink
Carla C. BaanCarla C. Baan
Carla C. Baan
Extracellular vesicles (EVs) are nanoparticles that transmit molecules from releasing cells to target cells. Recent studies link urinary EVs (uEV) to diverse processes such as infection and rejection after kidney transplantation. This, and the unmet need for biomarkers diagnosing kidney transplant dysfunction, has led to the current high level of interest in uEV. uEV provide non-intrusive access to local protein, DNA, and RNA analytics without invasive biopsy. To determine the added value of uEV measurements for detecting allograft dysfunction after kidney transplantation, we systematically included all related literature containing directly relevant information, with the addition of indirect evidence regarding urine or kidney injury without transplantation. According to their varying characteristics, uEV markers after transplantation could be categorized into kidney-specific, donor-specific, and immune response-related (IR-) markers. A few convincing studies have shown that kidney-specific markers (PODXL, ion cotransporters, SYT17, NGAL, and CD133) and IR-markers (CD3, multi-mRNA signatures, and viral miRNA) could diagnose rejection, BK virus-associated nephropathy, and calcineurin inhibitor nephrotoxicity after kidney transplantation. In addition, some indirect proof regarding donor-specific markers (donor-derived cell-free DNA) in urine has been demonstrated. Together, this literature review provides directions for exploring novel uEV markers’ profiling complications after kidney transplantation.

19 December 2022 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Open access
LWLiang Wu
Liang Wu
WWWouter W. Woud
Wouter W. Woud
CBCarla C. Baan
Carla C. Baan
DHDennis A. Hesselink
Dennis A. Hesselink
EPEdwin van der Pol
Edwin van der Pol
KBKarin Boer
Karin Boer
Urinary extracellular vesicles (uEVs) are promising biomarkers for various diseases. However, many tools measuring uEVs rely on time-consuming uEV isolation methods, which could induce sample bias. This study demonstrates the detection of single uEVs without isolation using imaging flow cytometry (IFCM). Unstained urine samples contained auto-fluorescent (A-F) particles when characterized with IFCM. Centrifugation successfully removed A-F particles from the unprocessed urine. Based on the disappearance of A-F particles, a gate was defined to distinguish uEVs from A-F particles. The final readouts of IFCM were verified as single EVs based on detergent treatment and serial dilutions. When developing this protocol to measure urine samples with abnormally high protein levels, 25 mg/mL dithiothreitol (DTT) showed improved uEV recovery over 200 mg/mL DTT. This study provides an isolation-free protocol using IFCM to quantify and phenotype single uEVs, eliminating the hindrance and influence of A-F particles, protein aggregates, and coincidence events.

19 January 2024 in Chemical Engineering Journal
Verified
Journal Article
Closed access
XZXing Zhang
Xing Zhang
XLXiang Li
Xiang Li
MFMengying Fu
Mengying Fu
JMJeremiah Ong'AChwa Machuki
Jeremiah Ong'AChwa Machuki
WWWandong Wang
Wandong Wang
FGFenglei Gao
Fenglei Gao

6 September 2022 in Journal of Controlled Release
Verified
Journal Article
Open access
JVJ. Vos
J. Vos
HTHector Tejeda-Mora
Hector Tejeda-Mora
AMA. Merino
A. Merino
LWLiang Wu
Liang Wu
WWW.W. Woud
W.W. Woud
MHMartin J. Hoogduijn
Martin J. Hoogduijn
Vesicle-based medicines hold great promise for therapy development but essential knowledge on the bio-distribution and longevity of vesicles after administration is lacking. We generated vesicles from the membranes of human mesenchymal stromal cells (MSC) and we demonstrated earlier that these so-called membrane particles (MP) mediate immunomodulatory and regenerative responses in target cells. In the present study we examined the bio-distribution and longevity of MP after intravenous administration in mice. While most vesicle tracking methods are based on imaging techniques, which require labeling of vesicles and can only detect dense accumulations of vesicles, we used proteomics analysis to detect the presence of MP-derived proteins in multiple organs and tissues. MP proteins were mainly present in plasma and leukocytes at 1 h after injection, indicating that MP - in contrast to whole MSC - do not accumulate in the lungs upon first passage but remain in circulation. After 24 h, MP proteins were still present in plasma but were most abundant in the liver. RNA sequencing of livers demonstrated that MP impact liver function and in particular induce metabolic pathways. These data provide a clear view of the bio-distribution and longevity of MP, which is likely extrapolatable to other types of vesicles, and demonstrate that MP circulate for up to 24 h and may be a tool for targeting the liver.

1 April 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LWLiang Wu
Liang Wu
MHMartijn H van Heugten
Martijn H van Heugten
TBThierry Pp van Den Bosch
Thierry Pp van Den Bosch
HDHans Duimel
Hans Duimel
CLCarmen López-Iglesias
Carmen López-Iglesias
KBKarin Boer
Karin Boer
Purpose: Kidney transplantation is the optimal treatment for patients with end-stage kidney disease. Donor-specific urinary extracellular vesicles (uEVs) hold potential as biomarkers for assessing allograft status. We aimed to develop a method for identifying donor-specific uEVs based on human leukocyte antigen (HLA) mismatching with the kidney transplant recipients (KTRs). Patients and Methods: Urine and plasma were obtained from HLA-A2+ donors and HLA-A2- KTRs pre-transplant. CD9 (tetraspanin, EV marker) and HLA-A2 double-positive (CD9+ HLA-A2+) EVs were quantified using isolation-free imaging flow cytometry (IFCM). Healthy individuals’ urine was used to investigate CD9+ HLA-class-I+ uEV quantification using IFCM, time-resolved fluoroimmunoassay (TR-FIA), and immunogold staining cryo-electron microscopy (cryo-EM). Culture-derived CD9+ HLA-class-I+ EVs were spiked into the urine to investigate urine matrix effects on uEV HLA detection. Deceased donor kidneys and peritumoral kidney tissue were used for HLA class I detection with histochemistry. Results: The concentrations of CD9+ HLA-A2+ EVs in both donor and recipient urine approached the negative (detergent-treated) control levels for IFCM and were significantly lower than those observed in donor plasma. In parallel, universal HLA class I+ uEVs were similarly undetectable in the urine and uEV isolates compared with plasma, as verified by IFCM, TR-FIA, and cryogenic electron microscopy. Culture supernatant containing HLA class I+ vesicles from B, T, and human proximal tubule cells were spiked into the urine, and these EVs remained stable at 37°C for 8 hours. Immunohistochemistry revealed that HLA class I was predominantly expressed on the basolateral side of renal tubules, with limited expression on their urine/apical side. Conclusion: The detection of donor-specific uEVs is hindered by the limited release of HLA class I+ EVs from the kidney into the urine, primarily due to the polarized HLA class I expression on renal tubules. Identifying donor-specific uEVs requires further advancements in recognizing transplant-specific uEVs and urine-associated markers.

10 April 2025 in Transplantation Direct
Verified
Journal Article
Open access
LWLiang Wu
Liang Wu
Carla C. BaanCarla C. Baan
Carla C. Baan
DRDerek Reijerkerk
Derek Reijerkerk
DNDaan Msc Nieboer
Daan Msc Nieboer
TBThierry P.P. van den Bosch
Thierry P.P. van den Bosch
KBKarin Boer
Karin Boer
Background.: Urinary extracellular vesicles (uEVs) are nanosized particles primarily excreted by the kidney. Kidney-derived uEVs (kd-uEVs) are promising noninvasive biomarkers for assessing kidney allograft health and diseases such as acute rejection (AR) after kidney transplantation. However, their release dynamics posttransplant are unclear. This pilot study investigates kd-uEV dynamics and their potential to distinguish AR from acute tubular necrosis (ATN) and nonbiopsied controls. Methods.: In the discovery cohort, urine samples from 72 donor-recipient pairs were collected pretransplant and on posttransplant days 3, 7, 180, and before for-cause biopsies. A validation cohort included 28 recipients biopsied within the first 2 wk posttransplant. Urine was stained with CD63 (uEV marker) and kidney-specific markers aquaporin 2 (AQP2) or podocalyxin (PODXL). Kd-uEVs were quantified using imaging flow cytometry, and percentages among total CD63+ uEVs were calculated to adjust for urine dilution. Results.: The percentage of kd-uEVs was lower in pretransplant recipients (AQP2+: 1.1% [Q1–Q3, 0.3%–1.7%]; PODXL+: 1.5% [Q1–Q3, 0.9%–2.8%]) compared with donors (AQP2+: 4.7% [Q1–Q3, 0.9%–11.5%], P < 0.001; PODXL+ 6.4% [Q1–Q3, 1.4%–9.8%], P < 0.01). Recipients’ kd-uEVs remained on pretransplant levels on posttransplant day 3 but were higher on day 7 (AQP2+: 7.2% [Q1–Q3, 2.6%–17.4%], P < 0.001; PODXL+: 10.0% [Q1–Q3, 3.2%–16.3%], P < 0.001) and persisted until day 180. In the initial 2 wk after transplantation, AR cases had higher AQP2+ kd-uEVs (17.6% [Q1–Q3, 8.6%–32.3%]) than nonbiopsied controls (6.8% [Q1–Q3, 2.1%–11.2%], P < 0.05) and ATN (1.6% [Q1–Q3, 0.5%–6.4%], P < 0.01), with similar observations for PODXL+ kd-uEVs. This difference between early AR and ATN was validated in the validation cohort. Conclusions.: Kd-uEV release is prominent from day 7 posttransplant. Elevated kd-uEVs are associated with AR, distinguishing it from ATN and demonstrating their potential as noninvasive biomarkers for early AR diagnosis.